TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31231918

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 μg/kg (Group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 μg/kg (Group B)
Number of subjects: 54
Study: 28544533

Group type: EXPERIMENTAL
Intervention: Secukinumab (pooled)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 25294552

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colorectal resection
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 52
Study: 23624890

Group type: EXPERIMENTAL
Intervention: Once-daily (QD) oral mesalazine (1.5 to 2.25 g/d)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Three-times-daily (TID) oral mesalazine
Number of subjects: 301
Study: 22067717

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Porcine dermis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Composite failure
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Mesh group
Number of subjects: 99
Study: 18095052

Group type: EXPERIMENTAL
Intervention: Tissucol/Tisseel fibrin glue
Number of subjects: 325

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 325
Study: 16580905

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g) + Tropisetron (5 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g) + Granisetron (3 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Acetaminophen (1 g) + Placebo (saline solution)
Number of subjects: 26
Study: 12751271

Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg bid)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg tid)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10705174

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 750 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9473972

Group type: EXPERIMENTAL
Intervention: Continuous concurrent visual feedback during practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous feedback during acquisition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No continuous feedback during practice
Number of subjects: 0
Study: 8182012

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 3214945

Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: RU 486 + Dexamethasone
Number of subjects: 8
Study: 31102927

Group type: EXPERIMENTAL
Intervention: Home-based HMD + vestibular rehabilitation protocol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vestibular rehabilitation
Number of subjects: 47
Study: 29551675

Group type: EXPERIMENTAL
Intervention: ticagrelor 90 mg twice per day for 2 years
Number of subjects: 300

Group type: COMPARATOR
Intervention: aspirin 81 mg twice per day for 2 years
Number of subjects: 300
Study: 26934973

Group type: EXPERIMENTAL
Intervention: Daily Engagement of Meaningful Activities (DEMA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 36
Study: 24507460

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (4,000 IU/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-dose vitamin D3 (600 IU/d)
Number of subjects: 42
Study: 23059774

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) maintenance therapy after induction with carboplatin and paclitaxel (CP)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (CP alone)
Number of subjects: 351
Study: 19535661

Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 153

Group type: COMPARATOR
Intervention: Individual appointments
Number of subjects: 153
Study: 17609910

Group type: EXPERIMENTAL
Intervention: Lirukang Granule (LRKG), 1 package orally thrice a day for 4 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rukuaixiao Tablet, 4 tablets orally thrice a day for 4 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lirukang Granule (LRKG)
Number of subjects: 100
Study: 15355137

Group type: EXPERIMENTAL
Intervention: Nonalignable differences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alignable differences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contextual constraints
Number of subjects: 0
Study: 12002519

Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS) applied in the morning after PSD for 4 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 10388228

Group type: EXPERIMENTAL
Intervention: AgNOR counts measured by silver staining method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-cadherin expression assessed by immunohistochemistry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between high P AgNOR and decreased E-cadherin expression
Number of subjects: 0
Study: 7882099

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) parenterally twice daily for 10 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 2239131

Group type: EXPERIMENTAL
Intervention: Diazepam (rectal solution every 12 hours when temperature is 38.5 degrees C or more)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Valproic acid (suppositories at times of fever)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Untreated controls from Denmark
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 219
Study: 267565

Group type: EXPERIMENTAL
Intervention: Walkhoff's iodoform paste
Number of subjects: 171

Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 171
Study: 6787702

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) 6 mg per day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GST)
Number of subjects: 16
Study: 31290776

Group type: EXPERIMENTAL
Intervention: Closed PIVC system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open PIVC system
Number of subjects: 0
Study: 31915550

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention on asthma management and proper use of inhalers
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 72
Study: 26672998

Group type: EXPERIMENTAL
Intervention: Group-based self-management program (8 biweekly meetings of 2.5 hours duration)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Group-based self-management program
Number of subjects: 137
Study: 25644033

Group type: EXPERIMENTAL
Intervention: Tramadol-acetaminophen
Number of subjects: 70

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 70
Study: 24308613

Group type: EXPERIMENTAL
Intervention: i.v. normal saline (20 mL/kg) plus observation
Number of subjects: 144

Group type: COMPARATOR
Intervention: observation alone
Number of subjects: 144
Study: 22049950

Group type: EXPERIMENTAL
Intervention: Single injection
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Peppered injections
Number of subjects: 19
Study: 18832042

Group type: EXPERIMENTAL
Intervention: Intra-arterial bolus of 40 microg PGE1 in addition to angioplasty
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 40 microg PGE1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no trial medication)
Number of subjects: 45
Study: 17335532

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Semi-fowler position
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Sitting up position
Number of subjects: 408
Study: 15257087

Group type: EXPERIMENTAL
Intervention: Low tidal volume (6 mL/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High tidal volume (12 mL/kg)
Number of subjects: 14
Study: 12385679

Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 500 mg ciprofloxacin
Number of subjects: 0
Study: 10087818

Group type: EXPERIMENTAL
Intervention: Continuous PKF (propofol 2‐10 mg.kg‐1.h‐1, ketamine 240 micrograms.kg‐1.h‐1 and fentanyl 0.4 microgram.kg‐1.h‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: GOI (N2O‐oxygen‐isoflurane)
Number of subjects: 22
Study: 7553406

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg, single intravenous dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoclopramide (2 mg/kg, multiple doses)
Number of subjects: 40
Study: 2111768

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) discontinuation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Valproate (VPA) discontinuation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) discontinuation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (stable therapy)
Number of subjects: 70
Study: 415439

Group type: EXPERIMENTAL
Intervention: Addition of 5-10 mmol phosphate (155-310 mg phosphorus) per 1000 kcal of nutrient solution during parenteral nutrition.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased phosphate dosage for hypophosphatemic patients with acute renal insufficiency.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum phosphate determination at the start of parenteral nutrition and every second day during the first week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum phosphate determination twice weekly after the first week of parenteral nutrition.
Number of subjects: 0
Study: 30407513

Group type: EXPERIMENTAL
Intervention: MVA‐EBO‐Z alone or in a heterologous prime‐boost regimen with ChAd3‐EBO‐Z
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ChAd3‐EBO‐Z followed by MVA‐EBO‐Z
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Accelerated 1‐week prime‐boost regimen
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: MVA‐EBO‐Z
Number of subjects: 78
Study: 28632595

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 614

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 614
Study: 26362623

Group type: EXPERIMENTAL
Intervention: Total pericardial closure with intrapericardial drain and pericardio-pleural window (closure group)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Partial closure of the pericardium (open group)
Number of subjects: 142
Study: 23855596

Group type: EXPERIMENTAL
Intervention: High-intensity strength training (75-90% 1RM)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Low-intensity strength training (30-40% 1RM)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Healthy living education
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Low-intensity strength training
Number of subjects: 372
Study: 21463068

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Concurrent Alcohol Dependence (AD)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Non-Alcohol Dependence (non-AD)
Number of subjects: 193
Study: 19802926

Group type: EXPERIMENTAL
Intervention: Individualised functional training programme (100 hours)
Number of subjects: 25
Study: 16886934

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Concurrent stress-management therapy
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Active medication and placebo (irrespective of drug condition)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Neurologists' ratings of improvement, participants' reports of improvement, daily headache recordings
Number of subjects: 169
Study: 15174784

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment-free period
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide treatment
Number of subjects: 19
Study: 12010587

Group type: EXPERIMENTAL
Intervention: Olive oil (OO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sunflower-seed oil (SO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO)
Number of subjects: 18
Study: 9475646

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1200 IUs once a day for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (cellulose‐based placebo pills once a day for 2 weeks)
Number of subjects: 12
Study: 8560135

Group type: EXPERIMENTAL
Intervention: L-dopa 100-200 mg
Number of subjects: 28
Study: 2227131

Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet (1200 kcal/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet (2400 kcal/day)
Number of subjects: 12
Study: 339933

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study: 29100842

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (participants' own faeces)
Number of subjects: 90
Study: 27138964

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C15-PAL module (anchor-based approach)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-BM22 and QLQ-C15-PAL QOL instruments
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C15-PAL module (distribution-based approach)
Number of subjects: 204
Study: 24846364

Group type: EXPERIMENTAL
Intervention: Transradial (TR) approach
Number of subjects: 103

Group type: COMPARATOR
Intervention: Transfemoral (TF) approach
Number of subjects: 103
Study: 21930686

Group type: EXPERIMENTAL
Intervention: IMM-101 0.1 mg (1 mg/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IMM-101 0.5 mg (5 mg/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IMM-101 1.0 mg (10 mg/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IMM-101 (all doses)
Number of subjects: 18
Study: 21045228

Group type: EXPERIMENTAL
Intervention: Active learning
Number of subjects: 30

Group type: COMPARATOR
Intervention: Text reading only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Text reading and video demonstration
Number of subjects: 30
Study: 17655512

Group type: EXPERIMENTAL
Intervention: Alprazolam ODT 1.0 mg under fasting conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alprazolam ODT 1.0 mg after a standard high-fat breakfast
Number of subjects: 16
Study: 16278574

Group type: EXPERIMENTAL
Intervention: Social skills training curriculum provided in a small group residential format over a 4-day period.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 64
Study: 12151926

Group type: EXPERIMENTAL
Intervention: ANH group (5-8 ml/kg of blood withdrawn before systemic heparinization and replaced with colloid solutions)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no hemodilution performed)
Number of subjects: 204
Study: 10495621

Group type: EXPERIMENTAL
Intervention: Cholagogum F Nattermann (dried extracts from Schöllkraut and Curcuma)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 7492867

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 119
Study: 1938512

Group type: EXPERIMENTAL
Intervention: 5-FU plus 2100 cGy to the liver
Number of subjects: 300

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 300
Study: 6756155

Group type: EXPERIMENTAL
Intervention: 1% prednisolone phosphate eyedrops
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 11
Study: 31469080

Group type: EXPERIMENTAL
Intervention: Technology-based peer-support intervention program (PIP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study: 27677771

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 155
Study: 26370552

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1352
Study: 24468996

Group type: EXPERIMENTAL
Intervention: ART-Immediate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART-Def
Number of subjects: 0

Group type: COMPARATOR
Intervention: HUU
Number of subjects: 0

Group type: COMPARATOR
Intervention: HEU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of ART initiation
Number of subjects: 0
Study: 22583789

Group type: EXPERIMENTAL
Intervention: PRO-FIT intervention (computer-tailored lifestyle advice and counselling)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: PRO-FIT*advice log
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Face-to-face counselling sessions
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Telephone booster calls
Number of subjects: 181
Study: 20425223

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA) administered within 4.5 hours of symptom onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant tissue plasminogen activator (rt-PA) administered within 3 hours of symptom onset
Number of subjects: 0
Study: 17406114

Group type: EXPERIMENTAL
Intervention: Individualized multimedia computer program (IMCP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard information from treating neurologist
Number of subjects: 57

Group type: COMPARATOR
Intervention: General knowledge of vascular risk factors
Number of subjects: 57

Group type: COMPARATOR
Intervention: Knowledge of treatment modalities
Number of subjects: 57
Study: 15750363

Group type: EXPERIMENTAL
Intervention: Herbal supplement for a 2-week period
Number of subjects: 37174

Group type: COMPARATOR
Intervention: Control group (no herbal supplement)
Number of subjects: 37174
Study: 11902251

Group type: EXPERIMENTAL
Intervention: Low-dose prostacyclin (2 ng/kg/min) added to the standard anesthetic protocol, started immediately before surgery and continued for a maximum of 48 hours.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (standard anesthetic protocol without prostacyclin)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-dose prostacyclin (2 ng/kg/min)
Number of subjects: 34
Study: 10468073

Group type: EXPERIMENTAL
Intervention: Stent implantation after catheter recanalization
Number of subjects: 110

Group type: COMPARATOR
Intervention: Balloon angioplasty alone (no stent group)
Number of subjects: 110
Study: 8654903

Group type: EXPERIMENTAL
Intervention: Dichotic listening tasks (verbal and nonverbal paradigms)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Elderly persons with marked dichotic deficits
Number of subjects: 4

Group type: COMPARATOR
Intervention: Young adults with normal hearing
Number of subjects: 4
Study: 1331444

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 3001952

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 31401532

Group type: EXPERIMENTAL
Intervention: Own brand cigarette (OB)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tobacco/Menthol 36 mg/ml ECIG
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tobacco/Menthol 0 mg/ml ECIG
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 36 mg/ml ECIG
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ECIG conditions
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nicotine-containing conditions
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Flavors
Number of subjects: 7
Study: 29106497

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 69

Group type: COMPARATOR
Intervention: No Candesartan (Control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cumulative doxorubicin equivalent dose ≥268 mg/m2
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Anthracycline therapy
Number of subjects: 69
Study: 26735316

Group type: EXPERIMENTAL
Intervention: Sit-Stand Workstation (SSW)
Number of subjects: 46
Study: 26423621

Group type: EXPERIMENTAL
Intervention: Moxifloxacin in SAD study
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Moxifloxacin in TQT study
Number of subjects: 49
Study: 23909550

Group type: EXPERIMENTAL
Intervention: ACDF with Cloward procedure or cervical intervertebral fusion cage
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ACDF
Number of subjects: 73
Study: 21368271

Group type: EXPERIMENTAL
Intervention: E2 supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 18
Study: 18210092

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition introduced immediately at optimal flow rate (25 Kcal/kg day(‐1))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Early enteral nutrition introduced gradually to reach optimal flow rate
Number of subjects: 100
Study: 16551764

Group type: EXPERIMENTAL
Intervention: Information about diagnosis
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Information about poor prognosis
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Knowledge of diagnosis (non-informed)
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Knowledge of poor prognosis (non-informed)
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Factors associated with being informed
Number of subjects: 1271
Study: 12672170

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Vitex agnus castus (AC) extract
Number of subjects: 41